Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 1420 | |
10 mg | In stock | $ 2380 | |
25 mg | In stock | $ 5248 | |
50 mg | In stock | $ 8115 |
Description | Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM). |
In vitro | Encorafenib (LGX818) is a potent drug that can prevents diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. Encorafenib (LGX818) (10 nM) suppresses the ERK/MAPK pathway and displays marked inhibition of pERK in A375, G361 and SK-MEL-24 cells. 10 nM Encorafenib (LGX818) treatment for 12 days potently inhibits colony formation in A375, G361 and SK-MEL-24 cells, but not in RPMI7951 and C8161 cells. Encorafenib (LGX818) treatment induces a steady increase in the β-catenin level in G361 cells over time. |
CAS No. | 1269440-17-6 |
Chemical Formula | C22H27ClFN7O4S |
Molecular Weight | 540.01 |
Solubility | DMSO: 50 mg/mL (92.59 mM, Need ultrasonic) |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom